Published Technical Disclosure Archive

Enhanced Implantable Cellular and Biotherapeutic Agent Delivery System

Publication ID: 24-11857673_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Implantable Cellular and Biotherapeutic Agent Delivery System,” Published Technical Disclosure No. 24-11857673_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857673_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,673.

Summary of the Inventive Concept

An improved implantable delivery system for cellular and biotherapeutic agents, featuring integrated nanophase morphologies and a minimally invasive implantation procedure, enhancing efficacy, safety, and patient comfort.

Background and Problem Solved

The original patent, 'Implantable cellular and biotherapeutic agent delivery canister', while innovative, has limitations in terms of agent delivery efficiency, material biocompatibility, and implantation complexity. The new inventive concept addresses these limitations by introducing enhanced nanophase tubular structures, controlled-release mechanisms, and minimally invasive implantation procedures.

Detailed Description of the Inventive Concept

The enhanced delivery system consists of a nanoporous material with integrated nanophase morphologies, enabling efficient fluid and diffusion exchange. The material is integrated with a rigid, implantable metal canister featuring a through-porous membrane, allowing for controlled agent release. The system also incorporates a biocompatible, implantable device with a bicontinuous morphology, ensuring optimal agent delivery and minimal tissue irritation. The implantation procedure is minimally invasive, reducing patient discomfort and recovery time.

Novelty and Inventive Step

The new inventive concept introduces novel nanophase tubular structures with optimized thickness and diameter ranges, controlled-release mechanisms, and minimally invasive implantation procedures, which are not present in the original patent. These enhancements provide significant improvements in agent delivery efficiency, safety, and patient comfort.

Alternative Embodiments and Variations

Alternative embodiments may include varying the nanophase tubular structure's material composition, thickness, and diameter ranges to optimize agent delivery for specific disease conditions. Additionally, the system could be adapted for use in various anatomical locations, such as subcutaneous, intramuscular, or intra-articular implantation.

Potential Commercial Applications and Market

The enhanced implantable delivery system has significant commercial potential in the fields of regenerative medicine, gene therapy, and immunotherapy, with potential applications in treating various diseases, including autoimmune disorders, cancer, and rare genetic conditions. The market for this technology is substantial, with an estimated global value of over $10 billion by 2025.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61F2/022
A A61 A61K31/337
A A61 A61K31/397
A A61 A61K31/436
A A61 A61K31/65
A A61 A61K31/7036
A A61 A61K35/28
A A61 A61K38/14
A A61 A61K38/1866
A A61 A61K38/22
A A61 A61K39/395
A A61 A61K47/02
A A61 A61M39/0247
A A61 A61M2039/027
A A61 A61M2039/0261
A A61 A61M2039/0276
A A61 A61M2205/04

Field of Art

Biomedical engineering, specifically implantable drug delivery systems and nanomaterials for therapeutic agent encapsulation, involving expertise in materials science, nanotechnology, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with advanced degree, working knowledge of nanoporous materials, implantable medical devices, and drug delivery mechanisms, familiar with fabrication techniques for medical-grade nanomaterials

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable engineering modifications to the source patent's core nanoporous implantable delivery system. The disclosed changes in nanophase tubular structure dimensions, material compositions, and delivery mechanisms are incremental improvements that would be obvious to a skilled practitioner seeking to optimize cellular and biotherapeutic agent encapsulation and release.

Obvious Combinations & Variations

Source Patent Element
Apertured metallic capsule with nanophase tubular structure for fluid exchange
PTD Variation
Modifying nanophase tubular structure thickness range from 8-200 microns to 5-150 microns and adjusting nanotube diameter from 20-5,000 nm to 10-1,000 nm
Obviousness Reasoning
Dimensional optimization of nanomaterials is a routine design choice for a PHOSITA seeking improved fluid exchange and agent delivery characteristics
Source Patent Element
Medical grade metal nanotubes (titanium, stainless steel)
PTD Variation
Introducing bicontinuous morphology and controlled-release mechanisms for enhanced agent delivery
Obviousness Reasoning
Modifying material structure to improve drug delivery is a predictable application of known materials science techniques in implantable medical devices
Source Patent Element
Implantable device for cellular and biotherapeutic agents
PTD Variation
Adding minimally invasive implantation procedure and expanding potential anatomical deployment locations
Obviousness Reasoning
Adapting implantation techniques and device configurations represents standard engineering problem-solving for improving medical device usability and patient outcomes
Source Patent Element
Nanoporous substrate with integrated nanotubes
PTD Variation
Implementing through-porous membrane and expanding material composition options
Obviousness Reasoning
Membrane design variations and material composition adjustments are expected iterative improvements for a PHOSITA seeking enhanced drug delivery performance
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857673, a person having ordinary skill in the art would find the variations disclosed in the Published Technical Disclosure to be obvious extensions of the prior art, representing predictable engineering modifications that do not rise to the level of non-obvious innovation. The incremental improvements in nanophase tubular structure, delivery mechanisms, and implantation techniques would be within the ordinary capabilities of a skilled practitioner in the field of implantable cellular and biotherapeutic agent delivery systems.

Original Patent Information

Patent NumberUS 11,857,673
TitleImplantable cellular and biotherapeutic agent delivery canister
Assignee(s)NanoVault Medical LLC